Novavax, Inc.
9920 Belward Campus Drive
Rockville,
MD 20850
United States - Map
Phone: 240-268-2000
Fax: 240-268-2100
Web Site: http://www.novavax.com
| Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing vaccines using its virus-like particle platform technology for infectious diseases. It develops vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, and Respiratory Syncytial Virus, as well as Varicella Zoster that causes shingles. The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza virus-like-particle-based vaccine candidates and therapeutic vaccine candidates against cancer, as well as adjuvants, biogeneric products, and other diagnostic products for the territory of India. It also has a strategic collaboration Xcellerex Inc. for the production of 2009 H1N1 influenza vaccine. Novavax, Inc. was founded in 1987 and is headquartered in Rockville, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. John Lambert , 56
Exec. Chairman |
$
30.00K | N/A | Dr. Rahul Singhvi Sc.D., M.B.A., 44
Chief Exec. Officer, Pres, Director and Member of Gov. Relations Committee |
N/A
| N/A | Mr. Raymond J. Hage Jr., M.B.A., 41
Sr. VP of Commercial Operations |
N/A
| N/A | Mr. James Robinson , 48
VP of Technical and Quality Operations |
$
232.00K | N/A | Mr. Frederick W. Driscoll , 58
Chief Financial Officer, VP and Treasurer |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.09 (2.81%) 
Profile
